Sunday, September 24, 2023
Immunotherapy has been shown to be beneficial in the first- and second-line setting for multiple solid tumor types. The quickly changing landscape of available therapies and indications can make selection and use of immunotherapies challenging. Additionally, the understanding of combination treatments and management of immune-related adverse reactions is quickly evolving.
Supported by an independent educational grant from
AstraZeneca Pharmaceuticals LP
Steering Committee Chair
Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, United States
Professor of Medicine, Aix-Marseille University, Marseille, France
Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Professor of Medicine; Director of Genitourinary Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Associate Professor of Medicine; Chief of Medical Oncology, National Kapodistrian University of Athens Medical School, Attikon University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic Research Institute, Athens, Greece
Deputy Director, Immunotherapeutics Group; Assistant Attending, Gastrointestinal Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; BioMarck Pharmaceuticals; EMD Serono, Inc.; Genentech, Inc.; Pfizer Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Celgene Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Clovis Oncology; F. Hoffmann-La Roche Ltd; Lilly; Merck & Co., Inc; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Lilly; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pierre Fabre
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Clovis Oncology; F. Hoffmann-La Roche Ltd; Lilly; Merck & Co., Inc; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Guardant Health
Received grants for clinical research from: Carevive Systems; Incyte Corporation; Merck & Co., Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Merck & Co., Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Dendreon Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
Owns stock, stock options, or bonds from: Dual Therapeutics
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Genentech, Inc.; IFM Therapeutics; Kymab; MedImmune, Inc.; Merck & Co., Inc.; Pfizer Inc.; Pieris Pharmaceuticals, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; MedImmune, Inc.; Merck & Co., Inc.; Pfizer Inc.